INFORMATIONAL PURPOSES ONLY. Not medical, legal, or travel advice. Verify with official sources before acting. See corrections log.
Regenerative medicine laws and requirements in Mississippi. Citations, verification dates, and source links for every data point.
| Dimension | Value | Citation | Source | Verified | Confidence |
|---|---|---|---|---|---|
| Permit Unapproved Cell Therapies | permit cell therapies | Miss. Code Ann. § 41-131-1 (as amended by SB 2830, 2020)“The adult autologous mesenchymal stem cell, investigational drug, biological product or device must have successfully completed phase one of a clinical trial but has not been approved for general use by the United States Food and Drug Administration” | Link | 2026-10-09 | high |
| Require Patient Disclosure for Cell Therapies | require disclosure | Miss. Code Ann. § 41-131-1(2)(a)(iv), (2)(d)“(iv) Has given written informed consent, which shall be at least as comprehensive as the consent used in clinical trials for the use of the adult autologous mesenchymal stem cell, investigational drug, biological product or device”Note: Statutory written informed consent with specified contents (approved alternatives, outcomes, cost liability); no posted/advertising notice. | Link | 2026-10-09 | high |
| Limit Practitioner Scope for Cell Therapies | Requires a physician's prescription or recommendation; statute does not specify who administers. Product must be IRB-approved or in an FDA/NIH-approved protocol, have completed phase 1, and remain under investigation. | Miss. Code Ann. § 41-131-1(2)(a)(iii), (2)(b)“(iii) Has received a prescription or recommendation from the person's physician for an adult autologous mesenchymal stem cell, investigational drug, biological product or device;”Note: Peer-reviewed review (PMC11010147) agrees: 'the Mississippi legislation neither requires IRBs to report treatments nor stipulates that physicians administer the treatment.' | Link | 2026-10-09 | high |
| Have Cell Therapy Statute References | Miss. Code Ann. § 41-131-1 (Right-to-Try Act, as amended by SB 2830, 2020) | Mississippi SB 2830 (2020)“AN ACT TO AMEND SECTION 41-131-1, MISSISSIPPI CODE OF 1972, TO REVISE THE DEFINITION OF "ELIGIBLE PATIENT" TO INCLUDE THOSE PATIENTS WITH A TRAUMATIC INJURY;”Note: Stored '41-121-1' is incorrect; the provision is § 41-131-1. Bill history shows 'Approved by Governor' 06/25. | Link | 2026-10-09 | high |
View full Mississippi profile (all layers) · Report an error on this page